Is Addus HomeCare (ADUS) Undervalued As Acquisitions And Medicaid Exposure Come Into Focus?
Addus HomeCare (ADUS) heads into its September 15 presentation at the Jefferies Healthcare Services and Technology Conference with investors focused on how management frames recent acquisition activity and Medicaid exposure.
Recent price action has cooled a little, with the share price down 2.9% over the past week, even after a 23.5% gain across 90 days. A 3-year total shareholder return of 38.5% points to momentum that investors now seem to be reassessing as Addus HomeCare leans into acquisitions and higher Medicaid exposure.
Scan for other home care and Medicaid exposed operators with similar acquisition stories by reviewing the hand picked list of solid balance sheet and fundamentals (22 results) that could complement your view on Addus HomeCare.
For Addus HomeCare, that 23.5% move over 90 days and the recent pullback could either mirror sturdier fundamentals or just a swing in mood. The valuation work now needs to show which story fits.
Most Popular Narrative: 13% Undervalued
The most followed valuation storyline for Addus HomeCare pegs fair value at $132.69, above the recent $115.88 close, which puts the current pullback in a different light as investors weigh acquisition limits and Medicaid mix against that upside case.
Recent and upcoming state-level reimbursement rate increases in major markets (Illinois and Texas) are expected to add over $35 million in annualized revenue at stable 20%+ margins, directly supporting top-line growth and net margin expansion.
Consistently strong organic growth in the core Personal Care segment, driven by robust hiring, technology-enabled operations, and improving same-store service volumes, positions Addus to further capitalize on the preference for aging-in-place and rising demand for home-based care, boosting recurring revenue and operating leverage.
See why 12 investors see Addus HomeCare as 13% undervalued.
Result: Fair Value of $132.69 (UNDERVALUED)
Still, the narrative around Addus HomeCare can be knocked off course if tighter Medicare reimbursement and higher caregiver wage pressure squeeze the already thin margins that investors are banking on.
Find out about the key risks to this Addus HomeCare narrative.
Next Steps
If the Addus HomeCare story so far feels mixed, that is the point, and it is why your own read of the numbers matters. To see what current optimism is built on, review the 4 key rewards.
Looking for more Addus HomeCare style investment ideas?
Do not stop with Addus HomeCare. Use the Simply Wall Street Screener to quickly surface fresh ideas that match the way you already think about risk and opportunity.
- Target sturdier balance sheets and dependable fundamentals by reviewing the list of solid balance sheet and fundamentals (22 results) that could suit a more capital-protection focused approach.
- Hunt for quality at a discount by checking the 34 high quality undervalued stocks that may line up with your view on price versus business strength.
- Prioritise steady profiles with fewer red flags by scanning the 11 resilient stocks with low risk scores that can round out a portfolio without stretching your risk tolerance.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com